Do analysts prefer ADXN or AYTU?

Aytu BioPharma has a consensus price target of $10.75, suggesting a potential upside of 351.68%. Given Aytu BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe Aytu BioPharma is more favorable than Addex Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aytu BioPharma 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer ADXN or TXMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer PLRZ or ADXN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, PLRZ or ADXN?

Polyrizon has higher earnings, but lower revenue than Addex Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polyrizon N/A N/A -$3.34M N/A N/A Addex Therapeutics $210K 34.85 -$8.12M -$5.94 N/A

Is PLRZ or ADXN more profitable?

Polyrizon's return on equity of 0.00% beat Addex Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Polyrizon N/A N/A N/A Addex Therapeutics N/A -134.76% -106.00%

Do analysts prefer CTXR or ADXN?

Citius Pharmaceuticals presently has a consensus target price of $5.00, indicating a potential upside of 638.55%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Citius Pharmaceuticals is more favorable than Addex Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CTXR or ADXN more profitable?

Citius Pharmaceuticals' return on equity of -61.09% beat Addex Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Citius Pharmaceuticals N/A -61.09% -35.36% Addex Therapeutics N/A -134.76% -106.00%

Do analysts recommend DARE or ADXN?

Dare Bioscience currently has a consensus price target of $10.00, suggesting a potential upside of 635.29%. Given Dare Bioscience's stronger consensus rating and higher probable upside, research analysts plainly believe Dare Bioscience is more favorable than Addex Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is DARE or ADXN more profitable?

Dare Bioscience's return on equity of 0.00% beat Addex Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dare Bioscience N/A N/A -46.22% Addex Therapeutics N/A -134.76% -106.00%

Addex Therapeutics (ADXN) Competitors

$5.95 +0.15 (+2.59%)

As of 03:14 PM Eastern

Compare

ADXN vs. AYTU, TXMD, PLRZ, CTXR, and DARE

Should you buy Addex Therapeutics stock or one of its competitors? Addex Therapeutics's main competitors and comparable companies include Aytu BioPharma (AYTU), TherapeuticsMD (TXMD), Polyrizon (PLRZ), Citius Pharmaceuticals (CTXR), and Dare Bioscience (DARE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Addex Therapeutics compare to Aytu BioPharma?

Addex Therapeutics (NASDAQ:ADXN) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Addex Therapeutics has higher earnings, but lower revenue than Aytu BioPharma. Addex Therapeutics is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addex Therapeutics	$210K	34.85	-$8.12M	-$5.94	N/A
Aytu BioPharma	$66.38M	0.38	-$13.56M	-$4.58	N/A

Addex Therapeutics has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Aytu BioPharma's return on equity of -69.93% beat Addex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addex Therapeutics	N/A	-134.76%	-106.00%
Aytu BioPharma	-60.17%	-69.93%	-13.25%

In the previous week, Addex Therapeutics' average media sentiment score of 0.00 equaled Aytu BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Addex Therapeutics	Neutral
Aytu BioPharma	Neutral

Addex Therapeutics has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market.

Aytu BioPharma has a consensus price target of $10.75, suggesting a potential upside of 351.68%. Given Aytu BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe Aytu BioPharma is more favorable than Addex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aytu BioPharma	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

16.1% of Addex Therapeutics shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 15.0% of Addex Therapeutics shares are owned by company insiders. Comparatively, 4.9% of Aytu BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Aytu BioPharma beats Addex Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Addex Therapeutics compare to TherapeuticsMD?

Addex Therapeutics (NASDAQ:ADXN) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Addex Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

TherapeuticsMD has a net margin of 5.34% compared to Addex Therapeutics' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Addex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addex Therapeutics	N/A	-134.76%	-106.00%
TherapeuticsMD	5.34%	0.32%	0.23%

TherapeuticsMD has higher revenue and earnings than Addex Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addex Therapeutics	$210K	34.85	-$8.12M	-$5.94	N/A
TherapeuticsMD	$3.02M	7.97	-$570K	$0.06	34.67

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Addex Therapeutics' average media sentiment score of 0.00 equaled TherapeuticsMD'saverage media sentiment score.

Company	Overall Sentiment
Addex Therapeutics	Neutral
TherapeuticsMD	Neutral

16.1% of Addex Therapeutics shares are held by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are held by institutional investors. 15.0% of Addex Therapeutics shares are held by insiders. Comparatively, 1.7% of TherapeuticsMD shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

TherapeuticsMD beats Addex Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Addex Therapeutics compare to Polyrizon?

Polyrizon (NASDAQ:PLRZ) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

Polyrizon has a beta of -1.5, meaning that its share price is 250% less volatile than the broader market. Comparatively, Addex Therapeutics has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Polyrizon's return on equity of 0.00% beat Addex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
Addex Therapeutics	N/A	-134.76%	-106.00%

Polyrizon has higher earnings, but lower revenue than Addex Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
Addex Therapeutics	$210K	34.85	-$8.12M	-$5.94	N/A

16.1% of Addex Therapeutics shares are owned by institutional investors. 15.0% of Addex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Polyrizon's average media sentiment score of 0.00 equaled Addex Therapeutics'average media sentiment score.

Company	Overall Sentiment
Polyrizon	Neutral
Addex Therapeutics	Neutral

Summary

Addex Therapeutics beats Polyrizon on 4 of the 7 factors compared between the two stocks.

How does Addex Therapeutics compare to Citius Pharmaceuticals?

Citius Pharmaceuticals (NASDAQ:CTXR) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

Addex Therapeutics has higher revenue and earnings than Citius Pharmaceuticals. Addex Therapeutics is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.13	N/A
Addex Therapeutics	$210K	34.85	-$8.12M	-$5.94	N/A

Citius Pharmaceuticals' return on equity of -61.09% beat Addex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Pharmaceuticals	N/A	-61.09%	-35.36%
Addex Therapeutics	N/A	-134.76%	-106.00%

16.9% of Citius Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are owned by institutional investors. 5.0% of Citius Pharmaceuticals shares are owned by insiders. Comparatively, 15.0% of Addex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Citius Pharmaceuticals presently has a consensus target price of $5.00, indicating a potential upside of 638.55%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Citius Pharmaceuticals is more favorable than Addex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Citius Pharmaceuticals had 3 more articles in the media than Addex Therapeutics. MarketBeat recorded 3 mentions for Citius Pharmaceuticals and 0 mentions for Addex Therapeutics. Citius Pharmaceuticals' average media sentiment score of 0.34 beat Addex Therapeutics' score of 0.00 indicating that Citius Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Citius Pharmaceuticals	Neutral
Addex Therapeutics	Neutral

Citius Pharmaceuticals has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, Addex Therapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market.

Summary

Citius Pharmaceuticals beats Addex Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Addex Therapeutics compare to Dare Bioscience?

Dare Bioscience (NASDAQ:DARE) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

6.7% of Dare Bioscience shares are held by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are held by institutional investors. 4.1% of Dare Bioscience shares are held by company insiders. Comparatively, 15.0% of Addex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Dare Bioscience's return on equity of 0.00% beat Addex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	N/A	N/A	-46.22%
Addex Therapeutics	N/A	-134.76%	-106.00%

Dare Bioscience has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, Addex Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market.

Dare Bioscience currently has a consensus price target of $10.00, suggesting a potential upside of 635.29%. Given Dare Bioscience's stronger consensus rating and higher probable upside, research analysts plainly believe Dare Bioscience is more favorable than Addex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Addex Therapeutics has lower revenue, but higher earnings than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than Addex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	19.91	-$13.40M	-$0.95	N/A
Addex Therapeutics	$210K	34.85	-$8.12M	-$5.94	N/A

In the previous week, Dare Bioscience had 3 more articles in the media than Addex Therapeutics. MarketBeat recorded 3 mentions for Dare Bioscience and 0 mentions for Addex Therapeutics. Dare Bioscience's average media sentiment score of 0.00 equaled Addex Therapeutics'average media sentiment score.

Company	Overall Sentiment
Dare Bioscience	Neutral
Addex Therapeutics	Neutral

Summary

Dare Bioscience beats Addex Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Addex Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADXN vs. The Competition

Export

Metric	Addex Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.32M	$11.95B	$7.06B	$12.95B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	-1.00	788.51	269.75	24.73
Price / Sales	34.85	967.70	652.34	108.63
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	1.27	10.33	11.27	6.42
Net Income	-$8.12M	$2.77B	$3.45B	$347.12M
7 Day Performance	1.73%	2.04%	3.56%	2.48%
1 Month Performance	-6.15%	-1.57%	-0.58%	-1.04%
1 Year Performance	-24.43%	191.33%	77.52%	23.22%

Addex Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADXN Addex Therapeutics	0.6098 of 5 stars	$5.95 +2.6%	N/A	-29.3%	$7.32M	$210K	N/A	30	Gap Up
AYTU Aytu BioPharma	1.8025 of 5 stars	$2.30 +4.1%	$10.75 +367.4%	-0.4%	$24.69M	$56.60M	N/A	160
TXMD TherapeuticsMD	1.1648 of 5 stars	$2.07 +1.5%	N/A	+94.4%	$23.96M	$3.35M	34.50	420	Upcoming Earnings
PLRZ Polyrizon	0.4412 of 5 stars	$11.25 +10.3%	N/A	+65.5%	$23.40M	N/A	N/A	N/A	Gap Down
CTXR Citius Pharmaceuticals	2.385 of 5 stars	$0.78 +25.4%	$5.00 +540.3%	-44.5%	$21.44M	N/A	N/A	20	News Coverage Upcoming Earnings High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADXN) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Addex Therapeutics (ADXN) Competitors

ADXN vs. AYTU, TXMD, PLRZ, CTXR, and DARE

How does Addex Therapeutics compare to Aytu BioPharma?

Summary

How does Addex Therapeutics compare to TherapeuticsMD?

Summary

How does Addex Therapeutics compare to Polyrizon?

Summary

How does Addex Therapeutics compare to Citius Pharmaceuticals?

Summary

How does Addex Therapeutics compare to Dare Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXN vs. The Competition

Addex Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Addex Therapeutics (ADXN) Competitors

ADXN vs. AYTU, TXMD, PLRZ, CTXR, and DARE

How does Addex Therapeutics compare to Aytu BioPharma?

Which has better valuation & earnings, ADXN or AYTU?

Is ADXN or AYTU more profitable?

Does the media prefer ADXN or AYTU?

Which has more risk & volatility, ADXN or AYTU?

Do analysts prefer ADXN or AYTU?

Do institutionals and insiders hold more shares of ADXN or AYTU?

Summary

How does Addex Therapeutics compare to TherapeuticsMD?

Which has more volatility & risk, ADXN or TXMD?

Is ADXN or TXMD more profitable?

Which has stronger earnings & valuation, ADXN or TXMD?

Do analysts prefer ADXN or TXMD?

Does the media prefer ADXN or TXMD?

Do institutionals and insiders have more ownership in ADXN or TXMD?

Summary

How does Addex Therapeutics compare to Polyrizon?

Which has more risk and volatility, PLRZ or ADXN?

Do analysts prefer PLRZ or ADXN?

Is PLRZ or ADXN more profitable?

Which has higher valuation & earnings, PLRZ or ADXN?

Do insiders and institutionals hold more shares of PLRZ or ADXN?

Does the media refer more to PLRZ or ADXN?

Summary

How does Addex Therapeutics compare to Citius Pharmaceuticals?

Which has stronger valuation & earnings, CTXR or ADXN?

Is CTXR or ADXN more profitable?

Do insiders & institutionals believe in CTXR or ADXN?

Do analysts prefer CTXR or ADXN?

Does the media refer more to CTXR or ADXN?

Which has more risk & volatility, CTXR or ADXN?

Summary

How does Addex Therapeutics compare to Dare Bioscience?

Do insiders and institutionals believe in DARE or ADXN?

Is DARE or ADXN more profitable?

Which has more risk & volatility, DARE or ADXN?

Do analysts recommend DARE or ADXN?

Which has stronger earnings & valuation, DARE or ADXN?

Does the media refer more to DARE or ADXN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXN vs. The Competition

Addex Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools